• Explore /
  • Poster
  • / AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

Sophia Frentzas

Sophia Frentzas

Medical Oncology, Monash Health, Melbourne, Victoria, Australia, School of Medical and Health Sciences, Monash University, Melbourne, VIC, Australia

Sophia Frentzas , Tarek Meniawy , Steven Chuan-Hao Kao , Ruihua Wang , Yunxia Zuo , Hao Zheng , Wei Tan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT04047862

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2583)

DOI

10.1200/JCO.2021.39.15_suppl.2583

Abstract #

2583

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jia Fan

First Author: Jia Fan

First Author: Jayesh Desai

Poster

2019 ASCO Annual Meeting

A phase I study evaluating COM701 in patients with advanced solid tumors.

A phase I study evaluating COM701 in patients with advanced solid tumors.

First Author: Drew W. Rasco